With the structure determination of liganded and unliganded Hb by Max Perutz in the 1960s and 1970s, (Perutz et al., 1960; Bolton and Perutz, 1970), the dawn of structure-based SCD drug discovery begun, and accelerated by the National Institutes of Health (NIH) request for applications to develop therapeutic agents to treat SCD based on the 3D structures of Hb. Here, GSTM1 is linked to Schnyder corneal dystrophy.